Patents Assigned to UCB Biopharma SRL
  • Patent number: 11975046
    Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
    Type: Grant
    Filed: June 29, 2023
    Date of Patent: May 7, 2024
    Assignees: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.
    Inventors: Timothy Scott Johnson, Breda Twomey, Janine Powers, Danielle E. Kellar
  • Patent number: 11942188
    Abstract: Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-molecular or inter-molecular atom to atom contacts extracted from a database of biological macromolecules to identify favoured regions adjacent to the binding site for particular atom types and modifying a candidate ligand to increase the intersection between atoms of the candidate ligand and the favoured regions. One or more steps of the methods may be performed by a computer.
    Type: Grant
    Filed: March 18, 2020
    Date of Patent: March 26, 2024
    Assignee: UCB Biopharma SRL
    Inventors: Jiye Shi, Terence Seward Baker, Alastair David Griffiths Lawson, Xiaofeng Liu
  • Patent number: 11919950
    Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
    Type: Grant
    Filed: December 15, 2020
    Date of Patent: March 5, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Ralph Adams, Terence Seward Baker, Alastair David Griffiths Lawson
  • Patent number: 11912721
    Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: February 27, 2024
    Assignees: UCB Biopharma SRL, Sanofi
    Inventors: Teresa De Haro Garcia, Michael Deligny, Jag Paul Heer, Joanna Rachel Quincey, Mengyang Xuan, Zhaoning Zhu, Daniel Christopher Brookings, Mark Daniel Calmiano, Yves Evrard, Martin Clive Hutchings, James Andrew Johnson, Sophie Jadot, Jean Keyaerts, Malcolm MacCoss, Matthew Duncan Selby, Michael Alan Shaw, Dominique Louis Leon Swinnen, Laurent Schio, Yann Foricher, Bruno Filoche-Romme
  • Patent number: 11905310
    Abstract: The present invention relates to a process for purification a protein comprising a semi-continuous chromatography step whereby the flow-through is collected and re-loaded onto the chromatography matrix.
    Type: Grant
    Filed: May 24, 2021
    Date of Patent: February 20, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventor: Michael Harry Rose
  • Patent number: 11884737
    Abstract: The present invention relates to a method of treating an autoimmune or inflammatory disease or a neurodegenerative disease with an antibody to CD154.
    Type: Grant
    Filed: June 29, 2021
    Date of Patent: January 30, 2024
    Assignees: UCB BIOPHARMA SRL, BIOGEN MA INC.
    Inventors: Ruth Oliver, Miren Zamacona
  • Publication number: 20240000893
    Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.
    Type: Application
    Filed: June 29, 2023
    Publication date: January 4, 2024
    Applicants: UCB BIOPHARMA SRL, FIVE PRIME THERAPEUTICS, INC.
    Inventors: Timothy Scott JOHNSON, Breda TWOMEY, Janine POWERS, Danielle E. KELLAR
  • Patent number: 11857625
    Abstract: The present invention relates to pharmaceutical compositions comprising from an antibody or a fragment thereof which binds IL-17A and IL-17F and a combination of glycine, acetate buffer at pH 4.6 to 5.5 and polysorbate 80.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: January 2, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sandrine Durran, Andrew Jeffrey Yates
  • Patent number: 11859203
    Abstract: The present invention relates to methods for reducing the heterogeneity of a population of recombinant proteins produced in cell culture, said methods comprising growing host cells producing a recombinant protein in a cell culture medium wherein the cell culture medium comprises one or more cysteine/cystine analogs.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: January 2, 2024
    Assignee: UCB BIOPHARMA SRL
    Inventors: Valentine Chevallier, Nadine Kochanowski, Laetitia Malphettes, Vincent Adolphe Carol Cool
  • Patent number: 11834514
    Abstract: The present invention provides method for increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises a) a thermal conversion step of holding the composition comprising the antibody molecule at a temperature in the range 30 to 60° C. for a period of at least 1 hour, wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: December 5, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Christopher John Le Page, Razwan Hanif
  • Patent number: 11807680
    Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: November 7, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Neesha Dedi, Breda Twomey, Michael John Wright, Gareth Charles Glyndwr Davies, David James McMillan
  • Patent number: 11786593
    Abstract: The present invention provides method of increasing the percentage of monomer in a composition of recombinantly expressed antibody molecules characterised in that the antibody molecule comprises at least one Fv with specificity for an antigen of interest comprising one VH and one VL wherein said VH and VL are connected directly or indirectly via one or more linkers and are stabilised by a disulfide bond therebetween, said method comprises: a) a conversion step of treating the composition with a denaturant selected from urea and/or Guanidine hydrochloride; b) wherein step a) is performed in the presence of a reducing agent or after treatment with a reducing agent.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: October 17, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Sam Philip Heywood, Gavin Barry Wild, Razwan Hanif, Christopher John Le Page
  • Patent number: 11746145
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: September 5, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Kerry Louise Tyson, Terence Seward Baker, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade, David Edward Ormonde Knight
  • Patent number: 11732034
    Abstract: The present invention relates to Tau-binding antibodies and binding fragments thereof.
    Type: Grant
    Filed: December 29, 2020
    Date of Patent: August 22, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: David Edward Ormonde Knight, Terence Seward Baker, David James McMillan, Robert Anthony Griffin, Georges Mairet-Coello, Patrick Downey, Jean-Philippe Courade
  • Patent number: 11710233
    Abstract: A machine-based learning method estimates a probability of bone fractures in a 3D image, more specifically vertebral fractures. The method and system utilizing such method utilize a data-driven computational model to learn 3D image features for classifying vertebra fractures. A three-dimensional medical image analysis system for predicting a presence of a vertebral fracture in a subject includes a 3D image processor for receiving and processing 3D image data of a 3D image of the subject, producing two or more sets of 3D voxels. Each of the sets of 3D voxels corresponds to an entirety of the 3D image and each of the sets of 3D voxels consists of equal 3D voxels of different dimensions. The system also includes a voxel classifier for assigning the 3D voxels one or more class probabilities each of the 3D voxels contains a fracture using a computational model, and a fracture probability estimator for estimating a probability of the presence of a vertebral fracture in the subject.
    Type: Grant
    Filed: April 21, 2022
    Date of Patent: July 25, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventor: Joeri Nicolaes
  • Patent number: 11692041
    Abstract: The present disclosure relates to constructs, such as antibody molecules comprising a binding domain specific to CD45, said binding domain comprising SEQ ID NO: 1, 2, 3 and/or SEQ ID NO: 4, 5 and 6. The disclosure also extends to pharmaceutical compositions comprising said constructs and use of the constructs/compositions in treatment.
    Type: Grant
    Filed: July 15, 2016
    Date of Patent: July 4, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Helene Margaret Finney, Stephen Edward Rapecki, Kerry Louise Tyson, Michael John Wright
  • Patent number: 11674967
    Abstract: A new, stable trimeric TNF? structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNF?/TNFR1 interaction. Membrane-bound TNF? is not affected in its ability to signal through TNFR2, and thus the new structure of TNF? may be used in therapies which do not significantly raise the risk of infection or malignancy.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: June 13, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: James Philip O'Connell, John Robert Porter, Alastair Lawson, Boris Kroeplien, Stephen Edward Rapecki, Timothy John Norman, Graham John Warrellow, Tracy Lynn Arakaki, Alex Buntin Burgin, William Ross Pitt, Mark Daniel Calmiano, David Andreas Schubert, Daniel John Lightwood, Rebecca Jayne Munro
  • Publication number: 20230074381
    Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
    Type: Application
    Filed: June 1, 2022
    Publication date: March 9, 2023
    Applicant: UCB Biopharma SRL
    Inventors: Helene Margaret Finney, Alastair David Griffiths Lawson, Stevan Graham Shaw, Bryan John Smith, Kerry Louise Tyson, Lara Kevorkian, Christoph Meier, Kaushik Sarkar, Paul Alan Atherfold
  • Patent number: 11576970
    Abstract: The invention relates to a liquid pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof, cyclodextrin and methionine. In addition, it relates to a method for reducing precipitation of an antibody or an antigen-binding fragment thereof in a liquid pharmaceutical formulation through addition of methionine and cyclodextrin. In particular, the liquid pharmaceutical formulations comprises an anti-sclerostin antibody, hydroxypropyl-gamma cyclodextrin and methionine and may be used in the treatment of a bone disorder associated with at least one of low bone formation, low bone mineral density, low bone mineral content, low bone mass, low bone quality and low bone strength, and especially for treating osteoporosis.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: February 14, 2023
    Assignee: UCB BIOPHARMA SRL
    Inventors: Andrew Jeffrey Yates, James Gregory Clipstone
  • Patent number: D999906
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: September 26, 2023
    Assignee: UCB Biopharma SRL
    Inventors: Barry Alan Knight, David Francis Philbrick